China Biologic Products Q4 Revenues Up
Gross profit increased 208.6% year-over-year to $27.3m, representing a gross margin of 72.7% as compared to 67.2% a year ago. The gross profit and margin increases were primarily
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
The study is thought to be the first ever demonstration in humans of targeted siRNA-containing nanoparticle delivery to tumors using systemic administration, delivery of functional siRNAs, and achievement